Program
etavopivat
Also written as “Etavopivat”, “Etavopivat Tablets Low dose” and “Etavopivat Tablets High dose”.
Its studies are mostly in Anemia, Sickle Cell · Thalassemia · Anemia · Liver Diseases, led by Novo Nordisk.
Furthest: phase 3, since Nov 5, 202012 company-led studies, 4 open or runningNext primary completion: Aug 20, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 124 open or running | phase 3since Nov 5, 2020 | Nov 5, 2020 | Aug 20, 2027phase 2 · NCT05953584 |
- Named in Novo Nordisk’s own pipeline as
Etavopivat
, phase 3, as of Nov 5, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 5, 2020First study: phase 3 study in Anemia, Sickle CellFirst studyNCT04624659 · 450 enrolled · United States, Canada, Egypt and more
- Jul 22, 2021Phase 2 study in Anemia, Sickle CellNCT04987489 · 53 enrolled · United States, Canada, Egypt and more
- Sep 15, 2022Phase 2 study in AnemiaNCT05568225 · 17 enrolled · United States, Canada, France and more
- Jan 23, 2023Phase 2 study in Anemia, Sickle CellNCT05725902 · 12 enrolled · United States
- Jul 11, 2023Phase 2 study in Anemia, Sickle CellNCT05953584 · 27 planned · India, Nigeria, Oman
- Dec 27, 2023Phase 2 study in Anemia, Sickle CellNCT06198712 · 95 planned · Canada, France, Kenya and more
- Mar 22, 2024Phase 1 study in Liver DiseasesNCT06336018 · 48 enrolled · United States
- May 22, 2024Phase 1 study in ThalassemiaNCT06433661 · 16 enrolled · United States
- Aug 30, 2024Phase 1 study in Anemia, Sickle CellNCT06581627 · 24 enrolled · China
- Sep 23, 2024Phase 3 study in Anemia, Sickle CellNCT06612268 · 510 planned · United States, Australia, Belgium and more
- Feb 3, 2025Phase 1 study in ThalassemiaNCT06813924 · 37 enrolled · United States
- Jun 8, 2025Phase 1 study in Anemia, Sickle CellNCT07023029 · 33 enrolled · United States
Ahead
- Aug 20, 2027Primary completion: phase 2 study in Anemia, Sickle CellNCT05953584
- Aug 27, 2027Primary completion: phase 3 study in Anemia, Sickle CellNCT06612268
- Feb 23, 2028Primary completion: phase 2 study in Anemia, Sickle CellNCT06198712
TargetBeta
“An orally available, small-molecule allosteric activator of the selective red blood cell (RBC) isoform of pyruvate kinase (PK-R), with potential to improve symptoms in sickly cell disease (SCD) patients. Upon oral administration, etavopivat allosterically binds to and activates PK-R, thereby enha…”NCIt, read by Claude
“Pyruvate kinase isozymes R/L activator”ChEMBL 37, by rule
Other programs on PKLR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mitapivatrule | Agios Pharmaceuticals | phase 4 | 24 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07023029Anemia, Sickle Cell · United States | 1 | Completed | Sep 12, 2025 | 33 |
| NCT06813924Thalassemia · United States | 1 | Completed | May 27, 2025 | 37 |
| NCT06612268Anemia, Sickle Cell · United States, Australia, Belgium and more | 3 | Recruiting | Aug 27, 2027 | 510 |
| NCT06581627Anemia, Sickle Cell · China | 1 | Completed | Oct 31, 2024 | 24 |
| NCT06433661Thalassemia · United States | 1 | Completed | Jul 6, 2024 | 16 |
| NCT06336018Liver Diseases · United States | 1 | Completed | Aug 1, 2025 | 48 |
| NCT06198712Anemia, Sickle Cell · Canada, France, Kenya and more | 2 | Recruiting | Feb 23, 2028 | 95 |
| NCT05953584Anemia, Sickle Cell · India, Nigeria, Oman | 2 | Recruiting | Aug 20, 2027 | 27 |
| NCT05725902Anemia, Sickle Cell · United States | 2 | Completed | Mar 9, 2026 | 12 |
| NCT05568225Anemia · United States, Canada, France and more | 2 | Terminated | Jul 15, 2024 | 17 |
| NCT04987489Anemia, Sickle Cell · United States, Canada, Egypt and more | 2 | Completed | Sep 3, 2025 | 53 |
| NCT04624659Anemia, Sickle Cell · United States, Canada, Egypt and more | 3 | Active, not recruiting | Feb 6, 2026 | 450 |
How it is read
Names in the registry
- “Etavopivat”, 10 entries
- “Etavopivat Tablets Low dose”, 1 entry
- “Etavopivat Tablets High dose”, 1 entry
- “Etavopivat Tablets”, 1 entry
- “Etavopivat tablets”, 1 entry
Conditions, from the studies’ own filings
- Anemia, Sickle Cell, 8 studies
- Thalassemia, 2 studies
- Anemia, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.